Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy.
Moira LancelotMaureen J MillerJohn RobackSean R StowellPublished in: Transfusion (2020)
This case illustrates not only that TTP may be a potential complication of checkpoint inhibitor therapy, but also that TTP developing in this setting may result in an unpredictable response to commonly employed TTP treatment modalities. Ultimately, checkpoint inhibitor-related TTP may require distinct management approaches and prognostic considerations.